Angptl3-integrin -induced podocyte lamellipodia and Rac1 activation via FAK-PI3 K phosphorylation. (a) F-actin in podocytes preincubated with 50 μM FAK inhibitor 14 for 1 h, followed by 250 ng/mL Angptl3 treatment for 15 min (B), 30 min (C), or no treatment (A). (b) F-actin in podocytes pre-incubated with 50 μM LY294002 for 0.5 h, followed by 250 ng/mL Angptl3 treatment for 15 min (B), 30 min (C), or no treatment (A). Scale bar, 20 μm. The comparison of lamellipodia formation between groups in (a) and (b) is shown in (c). Cells were not treated in the control group, were treated with 50 μM FAK inhibitor 14 or 50 μM LY294002 for 1 h in FAK inhibitor 14 group and LY294002 group, were treated with 250 ng/mL Angptl3 for 1 h in the Angptl3 group, or were treated with 50 μM FAK inhibitor 14 or 50 μM LY294002 for 1 h, followed by 250 ng/mL Angptl3 treatment for 1 h in FAK inhibitor 14 + Angptl3 group and LY294002 + Angptl3 group. The comparison of Rac1 activation levels between groups is shown in (d). **Compared to control group, . ##Compared to Angptl3 group, . (e) Phosphorylation of Y397FAK and p85-FAK in podocytes pre-incubated with echistatin, LY294002, or no inhibitor, followed by Angptl3 treatment.
